

VITROLIFE GROUP™

Vitrolife AB (publ)

Pre-silent call prior to Q3 2026

Pär Ihrskog, CFO

Q3 2026 – Group and organisational update

- **Market update**
- **Restructuring program** to rationalise the portfolio and exit low profit markets is on track and will be finalised by the end of Q3.
- **Share repurchase programme** is making good progress and is almost halfway completed. A detailed update will be provided in the Q3 report.
- **CEO transition:** the recruitment process is ongoing and no information on a new CEO can be shared at this stage. Bronwyn Brophy will remain in place for up to 12 months, ensuring strategic continuity and operational stability.
- **Americas leadership:** Erin Schardt appointed SVP and General Manager, Americas, adding South America to her North America leadership and joining the Executive Management Team.

Erin Schardt has been appointed Senior Vice President and General Manager, Americas

- Expanded role adds South America to her current leadership of North America.
- In her two-plus years with the Group: profitable growth in North America, high-performing teams, stronger customer partnerships and the region's transformation into one Vitrolife Group organisation.
- Joins the Executive Management Team (EMT); broad commercial and general management experience in medtech and genetics, plus deep Americas market knowledge.



Disclaimer

This presentation may contain estimates and forward-looking statements, which reflect the Management's current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there is no assurance that these statements are correct or will be achieved. The most important strategic and operative risks regarding Vitrolife AB (publ) and its subsidiaries business and field are described in the Management report, in the Annual Report. These are primarily constituted by macro-economic risks, operational risks and financial risks.